The argument that ONCS will remain a penny stock until it creates revenue is absurd. This entire biotechnology industry is based on speculation. ONCS is a penny stock for two reasons: First, no one knows about ONCS. Second, the expectations aren't too high.
With that said, take a look at PCYC, QCOR, JAZZ, and ACAD, but not as they sit today, but rather years ago. If ONCS data is good it will become one of those companies, and so far, all data looks great.
I completely agree. There are some irrational commentary on here. ONCS is a small biotech with tremendous promise-- and appeal as investors find out about the work that the company has put forth. This is a speculative stock worth investing in, because their science works.
I'm not sure if this is directed at biopumper? but I don't think he said its revenue thats holding back ONCS he stated there was no short term gain to be had thus no current interest in it...
Biotechs are just too hard to classify in a simple manner...you can find cases of great company's being under valued(ONCS) and #$%$ companies being over valued...see for instance CLSN(worth almost $10/share before phase II trials)